THE REGULATION OF rDNA TECHNOLOGY DERIVED DRUGS: BIOTECH SPECIFIC ASPECTS
March 11, 2010(Ended)The Rembrandt Hotel
London, United Kingdom
London, United Kingdom
WHY SHOULD YOU ATTEND?- Gain a refresher/update on the technical aspects specific to the regulation of rDNA derived medicinal products
- Improve your knowledge of the differences between the regulation of rDNA products and conventional small molecule drugs
- Compare experiences with delegates from across Europe
WHO SHOULD ATTEND?
- Life scientists moving into biotech regulatory affairs
- Technical and scientific decision makers in biotech start up operations
- Those with a life science background in the financial sector involved in due diligence or regulatory portfolio
- Those from small molecule backgrounds transferring to biotech product regulatory affairs
Venue
Address
11 Thurloe Place,
London,
United Kingdom
London,
United Kingdom
Prices *
545 Pound Sterling
Organization
Important
Please, check the conference website for possible changes, before you make any traveling
arrangements
* Prices are for evaluation only.
Articles/News/Press releases
- Correlation existing between the decreasing values of central corneal thickness and worsening of the field defect in primary open angle glaucoma (Health/Opthalmology)
- A Study of clinical profile and treatment outcome of DOTS regime in 250 pulmonary and extra pulmonary patients in Hamidia hospital ,Bhopal in the year 2011
- Infection Control
- Chronic lymphocytic leukemia and related disorders - Clinical
- Health conferences
- Attending Health conferences is beneficial not only for professionals
